135.34
+12.05%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Twist Bioscience
From its filings with the US Securities and Exchange Commission
Twist Bioscience is based in South San Francisco, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker TWST. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 30 September 2025, it reported revenue of $376.6m and a net loss of $77.7m. At that date it held total assets of $641.9m and shareholders' equity of $473.0m.
At Twist Bioscience Corporation, we work in service of our customers who are changing the world for the better. In fields such as health care, food/agriculture, industrial chemicals/materials and academic research, by using our products, our customers are developing ways to better lives and improve the sustainability of the planet. We believe Twist Bioscience is uniquely positioned to help accelerate their efforts and the faster our customers succeed, the better for all of us.
We have developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of our platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. We have miniaturized traditional chemical DNA synthesis reactions to write over 1,000,000 pieces of DNA (oligonucleotides) up to 500 bases through direct synthesis on each silicon chip, approximately the size of a large mobile phone, reducing by 99.8% the amount of chemicals we estimate would be used per gene as compared to plate-based synthesis. We have combined our silicon-based DNA writing technology with proprietary software, scalable commercial infrastructure and an e-commerce platform to create an integrated technology platform that enables us to achieve high levels of quality, precision, automation, and manufacturing throughput at a significantly lower cost and quicker than our competitors.
Quoted from its 10-K, filed 17 Nov 2025. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 31 Oct 2018
- Employees
- 979
- Website
- twistbioscience.com ↗
- Head office
- 681 GATEWAY BLVD., SOUTH SAN FRANCISCO, CA, 94080
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Dr. Emily LeproustChairman of the Board, Chief Executive Officer, since 2013$7.6m
- Mr. Patrick FinnPresident, Chief Operating Officer$3.9m
- Mr. Adam LaponisChief Financial Officer$5.0m
- Ms. Paula GreenSenior Vice President - Human Resources$2.0m
- Mr. Robert WernerChief Accounting Officer, Vice President
- Mr. Dennis ChoChief Legal Officer and Corporate Secretary$1.8m
- Mr. Robert ChessLead Independent Director$307,481
- Ms. Trynka Shineman BlakeDirector
- Mr. Nelson ChanIndependent Director$284,981
- Mr. Keith CrandellIndependent Director$272,481
- Mr. Jan JohannessenIndependent Director$284,981
- Mr. Robert RagusaIndependent Director$277,481
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 33
- Environment
- 19
- Social
- 51
- Governance
- 28
- Direct emissions (scope 1)
- 6.27 t
- Energy emissions (scope 2)
- 14,315 t
- Women in the workforce
- 42%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Leading provider of synthetic DNA and gene synthesis services in the market.
- Strong reputation for high-quality products and customer satisfaction.
- Broad and diverse customer base across various industries.
- Extensive knowledge and expertise in synthetic biology and genomics.
Weaknesses
- Reliance on third-party suppliers for raw materials may affect supply chain stability.
- Limited presence in international markets, potentially missing out on global opportunities.
- Vulnerability to changes in government regulations regarding genetic engineering.
Opportunities
- Increasing demand for synthetic DNA and gene synthesis in various industries.
- Emerging markets and untapped potential in international expansion.
- Advancements in biotechnology and genomics present new opportunities for innovation.
Threats
- Intense competition from other synthetic biology companies in the market.
- Economic downturns and global market uncertainties may impact customer spending.
- Legal and ethical concerns surrounding genetic engineering may restrict business growth.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.